NSRX (Nasus Pharma) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSRX Nasus Pharma Ltd NSRX
14 GF Score
Price $3.09
! 4 Warning Signs
View Full Analysis

What is Nasus Pharma ROE % Adjusted to Book Value?

Nasus Pharma NSRX +6.29% 14 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Nasus Pharma's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Nasus Pharma's PB Ratio for the quarter that ended in Dec. 2025 was 29.80. Nasus Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 0.00%.

Nasus Pharma ROE % Adjusted to Book Value Related Terms

Nasus Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Nasus Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nasus Pharma ROE % Adjusted to Book Value Chart

Nasus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00

Nasus Pharma Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NSRX vs MIRA, SCLX, MDCX: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, Nasus Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nasus Pharma ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nasus Pharma's ROE % Adjusted to Book Value falls into.


NSRX
14GF Score
Nasus Pharma Ltd NSRX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nasus Pharma ROE % Adjusted to Book Value Calculation

Nasus Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 29.80
=0.00%

Nasus Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 29.80
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Nasus Pharma (NSRX) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nasus Pharma and its competitors.
Is Nasus Pharma's ROE % Adjusted to Book Value too high?
Nasus Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's ROE % Adjusted to Book Value compare to MIRA and SCLX?
Nasus Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nasus Pharma and its competitors. Nasus Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nasus Pharma Business Description

Address Yigal Alon 65, Tel Aviv, ISR, 6744317
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score

Get the complete analysis for NSRX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price